Phase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxIDOV-Immune A Viral Therapy Turning the Tide Against Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 for TTX-MC138: Breakthrough RNA Therapeutic Advances in Targeting Metastatic Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxFOR46: New Experimental Therapy Shows Tumor Shrinkage in Advanced Prostate Cancer Patients
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: China Approves Groundbreaking Drug for Bone Metastases SKB107
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025
- Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers July 28, 2025
- Newsletter 30/2025 July 27, 2025